Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose apatinib + camrelizumab + SOX first-line study in advanced gastric/gastroesophageal junction adenocarcinoma
ChiCTR2000034109Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, camrelizumab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Maximum tolerated dose and Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
Rivoceranibcamrelizumaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000034109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034109.